ILLUSTRATION. Residents walk on the Saara street market, amid the outbreak of the coronavirus disease (COVID-19), in Rio de Janeiro, Brazil, Wednesday (7/10/2020). REUTERS / Olivares Pillar
Source: Reuters | Editor: Barratut Taqiyyah Rafie
KONTAN.CO.ID – SAO PAULO/FRANFURT. Brazilian health authority Anvisa said on Wednesday (21/10/2020) that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and the University of Oxford had died. However, vaccine trials will continue.
Launch Reuters, Oxford confirmed plans to continue testing, saying in a statement that after careful assessment “there are no concerns about the safety of clinical trials.”
A source familiar with the matter told Reuters that the trial would be suspended if volunteers who died after receiving the Covid-19 vaccine indicated the person was part of a control group given the meningitis vaccine.
CNN Brazil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died from complications from Covid-19.
Also Read: Russia has detected more than 80 coronavirus mutations
Anvisa did not provide further details, citing the medical confidentiality of those involved in the trial.
AstraZeneca immediately declined to comment.
The Federal University of Sao Paulo, which helps coordinate phase 3 clinical trials in Brazil, separately said the volunteers were Brazilian citizens without disclosing where the person lived.
Also Read: These three provinces expressed readiness in implementing the corona vaccination
According to a university spokesperson, the continuity of the vaccine trials will be left up to the decision of the independent review board. The board is composed of experts not from AstraZeneca, or the Brazilian university or biomedical research center FioCruz which plans to produce a vaccine in Brazil.
<!–
